Last reviewed · How we verify
Activase
At a glance
| Generic name | Activase |
|---|---|
| Also known as | IV-tPA |
| Sponsor | Medical College of Wisconsin |
| Target | Plasminogen |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | discontinued |
Approved indications
- Acute myocardial infarction
- Ischemic stroke
- Pulmonary embolism
Common side effects
Key clinical trials
- Treatment with Intravenous Alteplase in Ischemic Stroke Patients with Onset Time Between 4.5 and 24 Hours (Phase 3)
- An Ancillary Imaging Study to the Intravascular Cooling in the Treatment of Stroke 2 (ICTuS 2) Trial, an NIH-funded Project on the Safety and Efficacy of Hypothermia Combined With Thrombolysis (Phase 2)
- Outcomes After Intravenous Alteplase / Tenecteplase With or Without Shuxuetong Injection in Routine Clinical Practice: A Patient Registry (N/A)
- Intra-Arterial Thrombolysis After SUCCESSful Angiographic Recanalization in Acute Large Vessel Occlusion Stroke of the Anterior Circulation: the IA-SUCCESS Multicenter, Randomized Clinical Trial (Phase 3)
- Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage (Phase 1)
- A Randomized Controlled Trial of Intra-arterial Reperfusion Therapy After Standard Dose Intravenous t-PA Within 4.5 Hours of Stroke Onset Utilizing Dual Target Imaging Selection. (Phase 2)
- Endovascular Stroke Treatment And Reteplase Protocol (Phase 2)
- Mechanical Opening Device Implantation Following Intravenous r-tPA and Recanalization Outcome Evaluation in Stroke Disease (MODIFIED) Trial (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |